Trials / Unknown
UnknownNCT02509234
Trabectedin and Irinotecan for Refractory Pediatric Sarcomas
Trabectedin and Irinotecan in Pediatric Refractory Sarcomas
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 30 (estimated)
- Sponsor
- Technical University of Munich · Academic / Other
- Sex
- All
- Age
- 10 Years – 40 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate patients with refractory childhood sarcomas, who have been treated with a combination therapy of trabectedin and irinotecan (within compassionate use), to determine, if this is a promising treatment option with acceptable toxicity and if the results warrant a prospective study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Combined chemotherapy with trabectedin followed by irinotecan | Day 1: Trabectedin 1,1 - 1,5 mg/m²/day i.v. Day 3-5 and 10-12: Irinotecan 30- 90 mg/m²/day p.o. or i.v. |
Timeline
- Start date
- 2014-02-01
- Primary completion
- 2016-07-01
- Completion
- 2017-07-01
- First posted
- 2015-07-27
- Last updated
- 2015-07-27
Source: ClinicalTrials.gov record NCT02509234. Inclusion in this directory is not an endorsement.